Update on proposed Share Reorganisation

Omega Diagnostics Group PLC

01 September 2023

 

Omega Diagnostics Group plc

('Omega' or the 'Company')

Update on proposed Share Reorganisation

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health and Nutrition products, announces an update with regards its proposed Share Reorganisation as notified in the Company's Notice of Annual General Meeting, which was posted to shareholders on 11 August 2023.

Proposed Share Reorganisation

Having consulted with a number of shareholders post the announcement of 31 August, the board has decided not to proceed with the proposed Share Reorganisation and associated consolidation of the Ordinary Shares. The board will withdraw Resolution 8 set out in the Notice of AGM with regards the Share Reorganisation.

Accordingly, the issued share capital of the Company will remain unchanged at 237,685,180 ordinary shares of 4 pence each and 123,245,615 deferred shares of 0.9 pence each.

The Company remains well funded and the Directors reiterate that they have no need or intention to raise funds at this time.

Contacts: 

Omega Diagnostics Group PLC		www.omegadx.com
Jag Grewal, Chief Executive Officer		via Walbrook PR
finnCap Ltd		Tel: [phone]
Geoff Nash / Edward Whiley / George Dollemore (Corporate Finance)
Nigel Birks / Harriet Ward (ECM)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus / Lianne Applegarth		Mob: [phone]
Sam Allen		Mob: [phone]

About Omega Diagnostics Group PLC

Omega (AIM: ODX) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.

www.omegadx.com

 

END